Clinical trial NCT03323736: In-Office Tympanostomy Tube Placement in Children (OTTER)
Official title: A Prospective, Single-arm, Multicenter Study to Evaluate Effectiveness and Safety of Tympanostomy Tube Placement Using the Tula Iontophoresis and Tube Delivery Systems for Children in an Office Setting.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: OME - Otitis Media With Effusion
AOM - Acute Otitis Media
Lead sponsor: Tusker Medical
Sponsor class: INDUSTRY
First posted: 2017-10-27
Enrollment: 370
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Pivotal cohort is single arm. Physician initial subjects evaluated in separate cohorts but not included in primary and secondary analyses.
Primary purpose: TREATMENT

Brief summary: A prospective, single-arm, multicenter study to evaluate effectiveness and safety of Tymbion iontophoresis and tympanostomy tube placement using the Tula Iontophoresis and Tube Delivery Systems for children in an office setting.

Detailed description: The objective of this study is to evaluate effectiveness and safety of tympanostomy tube (TT) placement in children following local anesthesia in a physician's clinic setting (henceforth referred to as 'in-office'). Local anesthesia using Tymbion, a lidocaine-based anesthetic, is delivered by the Tula Iontophoresis System (IPS) and TT placement is implemented by the Tula Tube Delivery System (TDS).

The IPS will be used to facilitate anesthetic delivery to the tympanic membrane (TM). The Iontophoresis System consists of an Iontophoresis Control Unit, Iontophoresis Earsets and a return electrode patch. The Control Unit monitors and delivers a fixed amount of charge (ie, dose) to the patient through the Earsets(s) and alerts the operator when charge delivery is complete. The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).

The TDS is a mechanical device that integrates a myringotomy blade, tympanostomy tube and tube inserter for TT placement with a user-controlled activation. The study will use the TDS with a grommet-type tube.

This pivotal study will include up to 422 children ages 6 months through 12 years indicated for tympanostomy tube placement enrolled at approximately 15 to 25 investigational centers in the US and Canada. The pivotal cohort consists of 222 subjects. In addition, up to 100 subjects will be enrolled as lead-in procedures in the OR using the TDS and up to 100 subjects will be enrolled as lead-in procedure in-office (using IPS and TDS) as the surgeons' initial experience with the technology prior to enrolling into the pivotal cohort.

All pivotal and lead-in subjects will follow the same study protocol assessments and visit schedule consisting of a screening visit, procedure visit and 3-week, 6 month, 12 month, 18 month, and 24 month post-procedure follow-up visits. Lead-in procedures will be analyzed separately from the pivotal pediatric cohort.

Eligibility criteria: Inclusion Criteria:

1. Males or females at least 6 months old through 12 years old at time of consent
2. Indication for tympanostomy tube insertion per Clinical Practice Guideline
3. Behavioral capacity and cooperative temperament to undergo an awake procedure, based on physician judgment (not applicable to OR Lead-In subjects)
4. Subject's parent/guardian and subject are able and willing to comply with the protocol and attend all study visits
5. Subject's parent/guardian and subject are able and willing to provide informed consent or assent as age appropriate

Exclusion Criteria:

1. Significantly atrophic, retracted, bimeric, monomeric or atelectatic tympanic membrane
2. Perforated tympanic membrane
3. Otitis externa
4. Active or recent conditions of the tympanic membrane (eg, prior myringotomy with incomplete wound healing or re-epithelization)
5. Hemotympanum
6. Damaged/denuded skin in the auditory canal
7. Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane potentially causing abrasion or irritation to the external ear canal
8. Anatomy that precludes sufficient visualization of and access to the tympanic membrane
9. Anatomy that necessitates tympanostomy tube placement in the posterior half of the tympanic membrane
10. History of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or any hypersensitivity to local anesthetics of the amide type, or any component of the anesthetic drug formulation (not applicable to OR Lead-In subjects)
11. Familial history of insensitivity to lidocaine or other local anesthetics of the amide type (eg, history of inadequate anesthesia with dental numbing agents). (not applicable to OR Lead-In subjects)
12. Electrically sensitive medical support systems (eg, pacemakers, defibrillators, cochlear implants)
13. Other conditions that would preclude performing the study procedure including iontophoresis system ear plug incompatibility.
14. Health conditions that, in the opinion of the investigator, would present undue risk to the subject, based on device/anesthetic drug product label warnings and precautions.
15. Subject is 4 years or older and not able to complete all baseline assessments. Subject is younger than 4 years and not able to complete all baseline assessments, not including audiometry.

Primary outcomes:
measure: Procedural Success:
timeFrame: Day of Procedure (Day 0) Immediately following tube placement
measure: Tube Placement Tolerability
timeFrame: Day of Procedure (Day 0) Immediately following tube placement
Secondary outcomes:
measure: Tube Patency
timeFrame: 3 Weeks Post Procedure
measure: Tube Retention
timeFrame: 3 Weeks Post Procedure
measure: Anesthesia Effectiveness
timeFrame: Day of Procedure (Day 0)
Other outcomes:
Locations:
city: Carlsbad
country: United States
facility: California Head and Neck Specialists
state: California
city: Roseville
country: United States
facility: Sacramento ENT
state: California
city: San Jose
country: United States
facility: Camino Ear Nose & Throat Clinic
state: California
city: Hartford
country: United States
facility: Connecticut Children's Medical Center
state: Connecticut
city: New Haven
country: United States
facility: Yale School of Medicine, Section of Otolaryngology
state: Connecticut
city: Fort Lauderdale
country: United States
facility: South Florida Pediatric Otolaryngology
state: Florida
city: Jacksonville
country: United States
facility: Nemour's Children's Specialty Care
state: Florida
city: Louisville
country: United States
facility: Advanced ENT & Allergy
state: Kentucky
city: Albany
country: United States
facility: Albany ENT & Allergy Services
state: New York
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Charlotte
country: United States
facility: Charlotte Ear Eye Nose & Throat Associates, PA
state: North Carolina
city: Bethlehem
country: United States
facility: Specialty Physician Associates
state: Pennsylvania
city: Lugoff
country: United States
facility: South Carolina Ear Nose and Throat
state: South Carolina
city: Orangeburg
country: United States
facility: Carolina Ear Nose and Throat Clinic
state: South Carolina
city: Abilene
country: United States
facility: Ear Nose and Throat Specialists of Abilene
state: Texas
city: Frisco
country: United States
facility: Frisco ENT for Children
state: Texas
city: Frisco
country: United States
facility: Collin County ENT
state: Texas
city: San Antonio
country: United States
facility: Ear Medical Group
state: Texas
city: Vancouver
country: Canada
facility: British Columbia Children's Hospital
state: British Columbia
Study officials:
affiliation: Columbia University
name: Lawrence Lustig
role: PRINCIPAL_INVESTIGATOR
References: